Navigation Links
Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
Date:10/18/2011

EAST BRUNSWICK, N.J. and IRVINE, Calif., Oct. 18, 2011 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and Stason Pharmaceuticals Inc. today announced they had entered into a collaboration agreement regarding the development of generic oral oncology products. Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories. Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

"This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio," said Jonathan Embleton, Chief Business Officer for Amerigen. "We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration."

"We have been working hard to leverage our high containment development and manufacturing capabilities," said Jim Fang, Chief Operating Officer for Stason. "This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal." 

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All of Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About Stason

Stason Pharmaceuticals Inc. is a California-based pharmaceutical company involved in the development and manufacture of oral pharmaceuticals products. Stason develops products for itself as well as providing contract development and manufacturing services to the industry. Stason operates out of an FDA inspected 16,000 sq. ft. manufacturing facility capable of handling SafeBridge Catetgory I-IV, high containment and high potency compounds.  

Contact:
Michelle Valsera
+1-732-993-9827
mvalsera@amerigenpharma.com


'/>"/>
SOURCE Amerigen Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):